REPLY
22.3.2024 09:31:34 CET | Business Wire | Press release
LEApedia, an AI-based assistant for warehouse management systems (WMS), won the coveted "Best Product LogiMAT 2024" award in the "Software, Communication & IT" category at the opening ceremony of LogiMAT 2024. The application is seamlessly integrated into the LEA Reply™ cloud-native SaaS WMS solution, offered by Logistics Reply, the Reply Group specialists in delivering innovative software solutions for the digital supply chain.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240322257679/en/
LEApedia revolutionizes the way you interact with your warehouse management system (WMS) and other supply chain tools, with the integration of a powerful multi-agent AI engine to enhance efficiency, streamline operations, and unlock new insights. LEApedia facilitates the analysis of vast datasets, enabling the identification of patterns and insights that were previously unattainable. (Graphic: Business Wire)
The award, which is considered one of the most coveted in the intralogistics industry, is presented at the International Trade Fair for Intralogistics and recognizes outstanding achievements in the logistics sector that significantly optimise internal logistics processes, reduce costs and increase productivity.
LEApedia, which helps to improve logistics management processes, stands at the forefront of warehouse management system (WMS) innovation powered by an advanced multi-agent AI engine. This engine facilitates the analysis of vast datasets, enabling the identification of patterns and insights that were previously unattainable. At its core, LEApedia leverages a state-of-the-art Language Model, designed to interpret and respond to natural language queries and commands. This capability ensures users can interact with the system efficiently, significantly improving usability and accessibility.
Furthermore, LEApedia's smart search functionality allows for quick and intuitive access to information, ranging from specific terms to complex process descriptions. This feature is instrumental in navigating the system, ensuring users can find the information they need with unprecedented ease and speed. LEApedia enhances the system's efficiency and user-friendliness, setting a new standard for WMS solutions.
LEApedia is tailored to the specific needs and software environment of each customer. This makes it suitable for small businesses as well as medium-sized handling centres and large players. The module can be integrated into the system in a very short timeframe without slowing down or interrupting operations. It can also be updated during regular business without disruptions.
"The LogiMAT 2024 award is further proof of the tremendous performance of our WMS solution, which we are continuously evolving to take time-to-value and quality to new levels and support our customers in every step of their digital transformation journey. Technologies such as generative AI and machine learning help improve supply chain visibility and enable proactive decision making. The LEApedia AI-powered assistant offers users new opportunities to efficiently scale their WMS during ongoing warehouse operations and compete in the dynamic logistics industry," concluded Enrico Nebuloni, Executive Partner at Reply.
Reply
Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
Logistics Reply
Logistics Reply provides cutting-edge software solutions that help companies achieve an efficient and more connected digital supply chain where different systems, partners, humans and machines seamlessly interact embracing the use of next-generation technologies such as AI, robotics, wearables and IoT. Logistics Reply accompanies its customers in this transformation journey ensuring rapid time-to-value and long-term quality results thanks to over 20 years of experience and deep knowledge of technologies and supply chain processes. www.lea.reply.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240322257679/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom